About the Event
In this installment of Pediatric Grand Rounds co-hosted by Dell Medical School’s Department of Pediatrics and Center for Rare Disease, Michio Hirano, M.D., presents “Emerging Therapies for Mitochondrial Diseases.” Hirano serves as chief of the Neuromuscular Medicine Division, director for the Muscular Dystrophy Association Clinic at Columbia University Irving Medical Center, and director for the H. Houston Merritt Center for Muscular Dystrophy and Related Diseases. He is the Lucy G. Moses Professor of Neurology at Columbia University’s Vagelos College of Physicians and Surgeons.
Email Pam Knight for the Zoom link.
Learning Objectives
By the end of this presentation, the audience participant should be able to:
- To recognize the duel genetic origins of mitochondria.
- To describe how preimplantation genetic testing (PGT) and mitochondrial replacement therapy (MRT) can reduce risk of transmission of mitochondrial DNA diseases.
- To recall the clinical presentation, genetic basis, and a FDA-approved treatment of thymidine kinase 2 deficiency (TK2d).
Target Audience
- Primary: Pediatricians, pediatric subspecialists, family medicine physicians, pediatric residents
- Secondary: Nursing and hospital Staff
Attributes/Competencies
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care, Medical Knowledge, Practice-based Learning and Improvement; Interpersonal and Communications Skills. Professionalism, Systems-based Practice
- IOM: Provide Patient-centered Care, Work in Interdisciplinary Teams, Employ Evidence-based Practice, Apply Quality Improvement, Utilize Informatics
- IECC: Interprofessional Teamwork & Team-based Practice
Disclosures
Michio Hirano, M.D., the speaker for this educational activity, is a consultant, advisory board member, speaker who receives speaking fees, provides contracted research, receives royalties and/or is a patent beneficiary to the following companies: Modis Therapeutics (subsidiary of Zogenix/UCB), Abliva Therapeutics, Stealth Biotherapeutics, Tisento Therapeutics, Apollo Medical Communications, American Academy of Neurology and Meducom.
The planners for this educational activity have no relevant financial relationship(s) with ineligible companies to disclose.
The CME Advisory Committee, reviewers of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this live course for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Rare Disease Week Activities at Dell Medical School
On Thursday, Feb. 26, Hirano presents the keynote lecture, “Neucleoside Therapy for Thymidine Kinase 2 Deficiency: From Mouse to FDA Approval,” and joins Z. Leah Harris, M.D., and Jewel Mullen, M.D., MPH, for a discussion on diagnostic and screening challenges for rare diseases. Learn more »
A new art exhibition, “Positive Exposure,” opens Feb. 26 in the Health Learning Building.